Role of lymph node removal in patients undergoing in surgery for Carcinoma Ovary after chemotherapy.

Role of lymphadenectomy in patients undergoing interval debulking surgery for Carcinoma Ovary

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/10/010031

Enrollment

120

Registered

2017-10-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- CA OVARY

Interventions

Intervention1: Routine Lymphadenectomy: Patients undergoing interval debulking Control Intervention1: No lymphadenectomy: Patients undergoing interval debulking

Eligibility

Inclusion criteria

Inclusion criteria: Patients who have undergone neoadjuvant chemotherapy for primary ovarian cancer or PPC followed by optimal interval debulking

Exclusion criteria

Exclusion criteria: Sub-optimal debulking, poor performance status

Design outcomes

Primary

Measure	Time frame
To determine the morbidity and mortality associated with pelvic & para-aortic lymphadenectomy in patients with epithelial ovarian cancer who undergo interval debulking (after chemotherapy)Timepoint: Immediate Post OP and then at 3 month intervals	—

Secondary

Measure	Time frame
Progression free survival and overall survivalTimepoint: At the end of 3 years and 5 years	—

Countries

India

Contacts

Public ContactAbraham Peedicayil

CMCH

sebastian.ajit@gmail.com09894746729

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026